Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-24T18:16:43.242Z Has data issue: false hasContentIssue false
  • English
  • Français

Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis

Published online by Cambridge University Press:  18 July 2016

D. J. Siskind ,
M. Harris ,
A. Phillipou ,
V. A. Morgan ,
A. Waterreus ,
C. Galletly ,
V. J. Carr ,
C. Harvey  and
D. Castle
D. J. Siskind*
Affiliation:
School of Medicine, The University of Queensland, Brisbane, Qld, Australia Metro South Addiction and Mental Health Service Health, Brisbane, Qld, Australia Policy and Epidemiology Group, Queensland Centre for Mental Health, Brisbane, Qld, Australia
M. Harris
Affiliation:
Policy and Epidemiology Group, Queensland Centre for Mental Health, Brisbane, Qld, Australia School of Public Health, The University of Queensland, Brisbane, Qld, Australia
A. Phillipou
Affiliation:
St Vincent's Hospital, Melbourne, Vic, Australia School of Medicine, The University of Melbourne, Melbourne, Vic, Australia
V. A. Morgan
Affiliation:
Neuropsychiatric Epidemiology Research Unit, School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Perth, Australia
A. Waterreus
Affiliation:
Neuropsychiatric Epidemiology Research Unit, School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Perth, Australia
C. Galletly
Affiliation:
School of Psychiatry, University of Adelaide, Adelaide, SA, Australia
V. J. Carr
Affiliation:
School of Psychiatry, University of New South Wales, Randwick, NSW, Australia Department of Psychiatry, Monash University, Clayton, Vic, Australia
C. Harvey
Affiliation:
School of Medicine, The University of Melbourne, Melbourne, Vic, Australia NorthWestern Mental Health, Melbourne, Vic, Australia
D. Castle
Affiliation:
St Vincent's Hospital, Melbourne, Vic, Australia School of Medicine, The University of Melbourne, Melbourne, Vic, Australia
*
*Address for correspondence: D. J. Siskind, MIRT, 519 Kessels Rd, MacGregor, Qld, Australia. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Aims.

Clozapine is the most effective medication for treatment refractory schizophrenia. However, descriptions of the mental health and comorbidity profile and care experiences of people on clozapine in routine clinical settings are scarce. Using data from the 2010 Australian Survey of High Impact Psychosis, we aimed to examine the proportion of people using clozapine, and to compare clozapine users with other antipsychotic users on demographic, mental health, adverse drug reaction, polypharmacy and treatment satisfaction variables.

Methods.

Data describing 1049 people with a diagnosis of schizophrenia or schizoaffective disorder, who reported taking any antipsychotic medication in the previous 4 weeks, were drawn from a representative Australian survey of people with psychotic disorders in contact with mental health services in the previous 12 months. We compared participants taking clozapine (n = 257, 22.4%) with those taking other antipsychotic medications, on a range of demographic, clinical and treatment-related indicators.

Results.

One quarter of participants were on clozapine. Of participants with a chronic course of illness, only one third were on clozapine. After adjusting for diagnosis and illness chronicity, participants taking clozapine had significantly lower odds of current alcohol, cannabis and other drug use despite similar lifetime odds. Metabolic syndrome and diabetes were more common among people taking clozapine; chronic pain was less common. Psychotropic polypharmacy did not differ between groups.

Conclusions.

Consistent with international evidence of clozapine underutilisation, a large number of participants with chronic illness and high symptom burden were not taking clozapine. The lower probabilities of current substance use and chronic pain among clozapine users warrant further study.

Keywords

Clozapinemetabolic syndromeschizophreniasubstance usetreatment refractory schizophrenia
Type
Original Articles
Information
Epidemiology and Psychiatric Sciences , Volume 26 , Issue 3 , June 2017 , pp. 325 - 337
Copyright
Copyright © Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agid, O, Arenovich, T, Sajeev, G, Zipursky, RB, Kapur, S, Foussias, G, Remington, G (2011). An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. Journal of Clinical Psychiatry 72, 1439–1444.Google Scholar
Alberti, KGMM, Eckel, RH, Grundy, SM, Zimmet, PZ, Cleeman, JI, Donato, KA, Fruchart, J-C, James, WPT, Loria, CM, Smith, SC, International Association for the Study of Obesity (2009). Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645.Google Scholar
Blair, JR, Spreen, O (1989). Predicting premorbid IQ: a revision of the National Adult Reading Test. Clinical Neuropsychologist 3, 129–136.Google Scholar
Castle, D, Morgan, V, Jablensky, A (2002). Antipsychotic use in Australia: the patients’ perspective. Australian and New Zealand Journal of Psychiatry 36, 633–641.Google Scholar
Castle, DJ, Jablensky, A, McGrath, JJ, Carr, V, Morgan, V, Waterreus, A, Valuri, G, Stain, H, McGuffin, P, Farmer, A (2006). The diagnostic interview for psychoses (DIP): development, reliability and applications. Psychological Medicine 36, 69–80.Google Scholar
Chong, SA, Remington, GJ, Bezchlibnyk-Butler, KZ (2000). Effect of clozapine on polypharmacy. Psychiatric Services (Washington, D.C.) 51, 250–252.Google Scholar
Craig, CL, Marshall, AL, Sjöström, M, Bauman, AE, Booth, ML, Ainsworth, BE, Pratt, M, Ekelund, U, Yngve, A, Sallis, JF, Oja, P (2003). International physical activity questionnaire: 12-country reliability and validity. Medicine and Science in Sports and Exercise 35, 1381–1395.Google Scholar
Crawford, JR, Deary, IJ, Starr, J, Whalley, LJ (2001). The NART as an index of prior intellectual functioning: a retrospective validity study covering a 66-year interval. Psychological Medicine 31, 451–458.Google Scholar
Drake, RE, Xie, H, McHugo, GJ, Green, AI (2000). The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin 26, 441–449.Google Scholar
Forrester, T, Siskind, D, Winckel, K, Wheeler, A, Hollingworth, S (2015). Increasing clozapine dispensing trends in Queensland, Australia 2004–2013. Pharmacopsychiatry 48, 164–169.Google Scholar
Gallego, JA, Nielsen, J, De Hert, M, Kane, JM, Correll, CU (2012). Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety 11, 527–542.Google Scholar
Galletly, CA, Foley, DL, Waterreus, A, Watts, GF, Castle, DJ, McGrath, JJ, Mackinnon, A, Morgan, VA (2012). Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry 46, 753–761.Google Scholar
Gee, S, Vergunst, F, Howes, O, Taylor, D (2014). Practitioner attitudes to clozapine initiation. Acta Psychiatrica Scandinavica 130, 16–24.Google Scholar
Gilmer, TP, Dolder, CR, Lacro, JP, Folsom, DP, Lindamer, L, Garcia, P, Jeste, DV (2004). Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161, 692–699.Google Scholar
Green, AI, Zimmet, SV, Strous, RD, Schildkraut, JJ (1999). Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard review of Psychiatry 6, 287–296.Google Scholar
Heatherton, TF, Kozlowski, LT, Frecker, RC, Fagerström, KO (1991). The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction 86, 1119–1127.Google Scholar
Henderson, DC, Nguyen, DD, Copeland, PM, Hayden, DL, Borba, CP, Louie, PM, Freudenreich, O, Evins, AE, Cather, C, Goff, DC (2005). Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. Journal of Clinical Psychiatry 66, 1116–1121.Google Scholar
Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. British Journal of Psychiatry: the Journal of Mental Science 201, 481–485.Google Scholar
Jablensky, A, McGrath, J, Herrman, H, Castle, D, Gureje, O, Evans, M, Carr, V, Morgan, V, Korten, A, Harvey, C (2000). Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Australian and New Zealand Journal of Psychiatry 34, 221–236.CrossRefGoogle Scholar
Kane, J, Honigfeld, G, Singer, J, Meltzer, H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789–796.Google Scholar
Kirkpatrick, B, Buchanan, RW, McKenney, PD, Alphs, LD, Carpenter, WT (1989). The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Research 30, 119–123.Google Scholar
Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Örey, D, Richter, F, Samara, M, Barbui, C, Engel, RR, Geddes, JR (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet 382, 951–962.Google Scholar
McEvoy, JP, Lieberman, JA, Stroup, TS, Davis, SM, Meltzer, HY, Rosenheck, RA, Swartz, MS, Perkins, DO, Keefe, RS, Davis, CE, Severe, J, Hsiao, JK (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163, 600–610.CrossRefGoogle Scholar
Meltzer, HY, Alphs, L, Green, AI, Altamura, AC, Anand, R, Bertoldi, A, Bourgeois, M, Chouinard, G, Islam, MZ, Kane, J, Krishnan, R, Lindenmayer, JP, Potkin, S, International Suicide Prevention Trial Study Group (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 82–91.Google Scholar
Mitchell, AJ, Vancampfort, D, Sweers, K, van Winkel, R, Yu, W, De Hert, M (2013). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–a systematic review and meta-analysis. Schizophrenia Bulletin 39, 306–318.Google Scholar
Morgan, VA, Waterreus, A, Jablensky, A, Mackinnon, A, McGrath, JJ, Carr, V, Bush, R, Castle, D, Cohen, M, Harvey, C, Galletly, C, Stain, HJ, Neil, AL, McGorry, P, Hocking, B, Shah, S, Saw, S (2012). People living with psychotic illness in 2010: the second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry 46, 735–752.Google Scholar
Morgan, VA, McGrath, JJ, Jablensky, A, Badcock, JC, Waterreus, A, Bush, R, Carr, V, Castle, D, Cohen, M, Galletly, C, Harvey, C, Hocking, B, McGorry, P, Neil, AL, Saw, S, Shah, S, Stain, HJ, Mackinnon, A (2013). Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychological Medicine, 1–14.Google Scholar
Morosini, PL, Magliano, L, Brambilla, L, Ugolini, S, Pioli, R (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica 101, 323–329.Google Scholar
Nasrallah, H, Morosini, P, Gagnon, DD (2008). Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Research 161, 213–224.CrossRefGoogle ScholarPubMed
Nielsen, J, Damkier, P, Lublin, H, Taylor, D (2011). Optimizing clozapine treatment. Acta Psychiatrica Scandinavica 123, 411–422.Google Scholar
Nielsen, J, Røge, R, Schjerning, O, Sørensen, HJ, Taylor, D (2012). Geographical and temporal variations in clozapine prescription for schizophrenia. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology 22, 818–824.Google Scholar
Patrick, DL, Burns, T, Morosini, P, Rothman, M, Gagnon, DD, Wild, D, Adriaenssen, I (2009). Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Current Medical Research and Opinion 25, 325–338.CrossRefGoogle ScholarPubMed
Pisani, F, Oteri, G, Costa, C, Di Raimondo, G, Di Perri, R (2002). Effects of psychotropic drugs on seizure threshold. Drug Safety 25, 91–110.Google Scholar
Randolph, C (1998). RBANS Manual: Repeatable Battery for the Assessment of Neuropsychological Status. The Psychological Corporation: San Antonio, TX.Google Scholar
Schretlen, DJ, Buffington, ALH, Meyer, SM, Pearlson, GD (2005). The use of word-reading to estimate ‘premorbid’ ability in cognitive domains other than intelligence. Journal of the International Neuropsychological Society: JINS 11, 784–787.Google Scholar
Seidel, S, Aigner, M, Ossege, M, Pernicka, E, Wildner, B, Sycha, T (2013). Antipsychotics for acute and chronic pain in adults. Cochrane Database of Systematic Reviews (Online) 8, CD004844.Google Scholar
Sernyak, MJ, Rosenheck, RA (2008). Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatric Services (Washington, DC) 59, 567–569.Google Scholar
Siskind, D, McCartney, L, Goldschlager, R, Kisely, S (2016). Clozapine versus first and second-generation antipsychotics in treatment refractory schizophrenia: systematic review & meta-analysis. British Journal of Psychiatry, in press.Google Scholar
Tang, Y-L, Mao, P-X, Jiang, F, Chen, Q, Wang, C-Y, Cai, Z-J, Mitchell, PB (2008). Clozapine in China. Pharmacopsychiatry 41, 1–9.Google Scholar
Taylor, DM, Young, C, Paton, C (2003). Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Journal of Clinical Psychiatry 64, 30–34.CrossRefGoogle ScholarPubMed
Taylor, DM, Smith, L, Gee, SH, Nielsen, J (2012). Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatrica Scandinavica 125, 15–24.Google Scholar
Tiihonen, J, Lönnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, A, Haukka, J (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620–627.CrossRefGoogle ScholarPubMed
Varma, S, Bishara, D, Besag, FMC, Taylor, D (2011). Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Therapeutic Advances in Psychopharmacology 1, 47–66.Google Scholar
Waterreus, A, Morgan, VA, Castle, D, Galletly, C, Jablensky, A, Di Prinzio, P, Shah, S (2012). Medication for psychosis–consumption and consequences: the second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry 46, 762–773.Google Scholar
Wing, JK, Babor, T, Brugha, T, Burke, J, Cooper, JE, Giel, R, Jablenski, A, Regier, D, Sartorius, N (1990). SCAN: schedules fonr clinical assessment in neuropsychiatry. Archives of General Psychiatry 47, 589–593.Google Scholar